Last reviewed · How we verify
NCT06250036: ZODIAC
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Phase 2 trial testing Single agent zimberelimab in Locally Advanced Gastric Adenocarcinoma in 50 participants. Currently enrolling.
20 March 2027
Quick facts
| Lead sponsor | Royal Marsden NHS Foundation Trust |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 20 February 2025 |
| Primary completion | 20 March 2027 |
| Estimated completion | 1 September 2031 |
| Sites | 9 locations across United Kingdom |
Drugs / interventions tested
- Single agent zimberelimab — full drug profile →
- Combination zimberelimab + domvanalimab — full drug profile →
Conditions studied
- Locally Advanced Gastric Adenocarcinoma — all drugs for Locally Advanced Gastric Adenocarcinoma →
- MSI-H/dMMR Gastric Cancer — all drugs for MSI-H/dMMR Gastric Cancer →
- MSI-H/dMMR Gastroesophageal-junction Cancer — all drugs for MSI-H/dMMR Gastroesophageal-junction Cancer →
Sponsor
Royal Marsden NHS Foundation Trust
Who can join
18 and older, any sex, with Locally Advanced Gastric Adenocarcinoma or MSI-H/dMMR Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer.
He P, Ma L, Xu B, Wang Y, et al · · 2024 · cited 7× · PMID 39091604 · DOI 10.1177/17588359241266156 -
Clinical status and future prospects of neoadjuvant immunotherapy for localized mismatch repair-deficient cancers: a review.
Li J. · · 2024 · cited 3× · PMID 38768473 · DOI 10.1097/js9.0000000000001680 -
Biology and evolving management of resectable dMMR/MSI-H cancers: current status and future perspectives.
Tanegashima T, Shiota M, Toyosaki K, Funakoshi K, et al · · 2025 · cited 1× · PMID 41196394 · DOI 10.1007/s00262-025-04223-9
Verify or expand the search:
- PubMed search for NCT06250036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced Gastric Adenocarcinoma
Currently open trials in the same condition.
- NCT05813015 — Study of Comparing of With and Without Sequential Therapy of S-1 · Phase 3 · recruiting
- NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT04007744 — Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors · Phase 1 · active not recruiting
Other Royal Marsden NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
- NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
- NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
- NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
- NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06250036 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
- Last refreshed: 21 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06250036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing